No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Jiangxi Fushine Pharmaceutical Co., Ltd. is engaged in the global research, development, production, and marketing of active pharmaceutical ingredients (APIs) and key chemical compounds for drug synthesis. Its product portfolio includes important antibiotics like penicillin and carbapenem, alongside a variety of other pharmaceutical offerings. The company also extends its expertise by providing contract research, development, and manufacturing services. Founded in 2002 and headquartered in Jingdezhen, China, the firm was initially named Jingdezhen Fuxiang Pharmaceutical Co., Ltd. before adopting its current designation in August 2012.
www.fushine.cnNo one on the platform currently holds 300497.SZ.
No tracked institution reports a position in 300497.SZ as of their last filing.
No one on the platform has traded 300497.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 0.3% | -4.6% | ||||
| Profit Margin % | -4.7% | -9.1% | 5.7% | |||
| Free Cash Flow Margin % | -13.7% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.2B | +79.3% | $1.29 | $1.29–$1.29 | — | 1 |
| 2027 | $2.7B | +19.6% | $1.76 | $1.76–$1.76 | — | 1 |
| 2028 | $3.1B | +16.9% | $2.16 | $2.16–$2.16 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300497.SZJiangxi Fushine Pharmaceutical Co., Ltd. | $22.05 | +5.40% | $11.9B | — |
| 000710.SZBerry Genomics Co.,Ltd | $8.39 | +0.36% | $3.0B | — |
| 002793.SZLuoxin Pharmaceuticals Group Stock Co., Ltd. | $4.47 | +0.22% | $4.9B | — |
| 003020.SZHefei Lifeon Pharmaceutical Co., Ltd. | $16.54 | +0.36% | $3.8B | — |
| 300147.SZXiangxue Pharmaceutical Co.,Ltd. | $6.37 | +0.16% | $4.2B | — |
| 300878.SZZhejiang Wecome Pharmaceutical Company Limited | $31.89 | +1.24% | $4.5B | — |
| 688075.SSAssure Tech (Hangzhou) Co., Ltd. | $28.15 | +0.72% | $3.6B | — |
Source: Financial Modeling Prep · peers by sector/industry